Literature DB >> 11472587

Denver developmental screening test II for early identification of the infants who will develop major neurological deficit as a sequalea of hypoxic-ischemic encephalopathy.

O Hallioglu1, A K Topaloglu, A Zenciroglu, O Duzovali, E Yilgor, S Saribas.   

Abstract

BACKGROUND: The primary aim of this study was to find widely available, inexpensive, and non-invasive parameters for early identification or prediction of the infants with hypoxic-ischemic encephalopathy (HIE) who will have a severe adverse outcome (classified as death or a major neurological deficit).
METHODS: Fifty-seven full-term or near-term newborn infants with a diagnosis of HIE were consecutively admitted to the neonatal intensive care unit and studied. Occurrence of seizures during the first 24 h, cranial ultrasonography (US) findings within the first 5 days of life, and Denver developmental screening test II (DDST II) at 6 months of age, were analyzed in relation to mortality and neurological status at 2 years of age.
RESULTS: Of the 57 infants, 10 were lost to follow-up. Twenty of the remaining 47 infants had a severe adverse outcome. Among the predictors of severe adverse outcome, occurrence of seizures was found to have a poor predictive accuracy. Cranial US had 100% sensitivity, however with a rather low specificity (55%). However, DDST II at 6 months of age, yielded a very high predictive accuracy (sensitivity=100%, specificity=95%).
CONCLUSION: We conclude that DDST II at 6 months of age could be used in predicting severe neurological outcome in infants with HIE.

Entities:  

Mesh:

Year:  2001        PMID: 11472587     DOI: 10.1046/j.1442-200x.2001.01418.x

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  5 in total

1.  Melatonin use for neuroprotection in perinatal asphyxia: a randomized controlled pilot study.

Authors:  H Aly; H Elmahdy; M El-Dib; M Rowisha; M Awny; T El-Gohary; M Elbatch; M Hamisa; A-R El-Mashad
Journal:  J Perinatol       Date:  2014-11-13       Impact factor: 2.521

2.  Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system.

Authors:  Sara E Oliver; Gretchen A Cloud; Pablo J Sánchez; Gail J Demmler; Wayne Dankner; Mark Shelton; Richard F Jacobs; Wendy Vaudry; Robert F Pass; Seng-jaw Soong; Richard J Whitley; David W Kimberlin
Journal:  J Clin Virol       Date:  2009-09-18       Impact factor: 3.168

3.  Evaluation of the psychometric properties of the Spanish version of the Denver Developmental Screening Test II.

Authors:  Beatriz De-Andrés-Beltrán; Ángel L Rodríguez-Fernández; Javier Güeita-Rodríguez; Johan Lambeck
Journal:  Eur J Pediatr       Date:  2014-08-28       Impact factor: 3.183

Review 4.  Intrapartum-related neonatal encephalopathy incidence and impairment at regional and global levels for 2010 with trends from 1990.

Authors:  Anne C C Lee; Naoko Kozuki; Hannah Blencowe; Theo Vos; Adil Bahalim; Gary L Darmstadt; Susan Niermeyer; Matthew Ellis; Nicola J Robertson; Simon Cousens; Joy E Lawn
Journal:  Pediatr Res       Date:  2013-12       Impact factor: 3.756

5.  Assessing Temporal Brain Metabolite Changes in Preterm Infants Using Multivoxel Magnetic Resonance Spectroscopy.

Authors:  Manami Akasaka; Atsushi Kamei; Nami Araya; Atsushi Matsumoto; Yu Konishi; Genichiro Sotodate; Satoko Shirasawa; Yukiko Toya; Takeo Kasai; Shoichi Chida; Makoto Sasaki
Journal:  Magn Reson Med Sci       Date:  2015-11-13       Impact factor: 2.471

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.